IN8bio, Inc. Files 8-K: Loan Agreement & Equity Updates
Ticker: INAB · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $0.3950, $0.3949, $12.4 m, $0.27 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, equity, material-agreement
TL;DR
IN8bio secured a loan and made equity changes, filing an 8-K on 9/30/24.
AI Summary
On September 30, 2024, IN8bio, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an affiliate of the Company. The company also reported on unregistered sales of equity securities and material modifications to the rights of its security holders. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates IN8bio, Inc. has secured financing through a loan agreement and has made changes related to its equity, which could impact its financial position and shareholder rights.
Risk Assessment
Risk Level: medium — The filing details financial agreements and equity changes, which inherently carry financial and operational risks for the company and its investors.
Key Players & Entities
- IN8bio, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Business Address City
FAQ
What type of Material Definitive Agreement did IN8bio, Inc. enter into on September 30, 2024?
IN8bio, Inc. entered into a loan agreement with an affiliate of the Company.
What other significant events are reported in this 8-K filing?
The filing also reports on unregistered sales of equity securities and material modifications to the rights of security holders.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated September 30, 2024.
In which state is IN8bio, Inc. incorporated?
IN8bio, Inc. is incorporated in Delaware.
What is the principal business address of IN8bio, Inc.?
The principal business address is 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 1,844 words · 7 min read · ~6 pages · Grade level 12.8 · Accepted 2024-10-01 16:59:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value INAB The Nasdaq Stock Mar
- $0.3950 — its will be sold at a purchase price of $0.3950 per unit (or $0.3949 per unit with resp
- $0.3949 — purchase price of $0.3950 per unit (or $0.3949 per unit with respect to units that inc
- $12.4 m — initial gross proceeds of approximately $12.4 million, before deducting placement agent
- $0.27 — Warrants will have an exercise price of $0.27 per share. The closing of the Private P
- $1.25 — , to (i) reduce the exercise price from $1.25 to $0.45 per share and (ii) extend the
- $0.45 — reduce the exercise price from $1.25 to $0.45 per share and (ii) extend the terminati
Filing Documents
- d895981d8k.htm (8-K) — 41KB
- d895981dex41.htm (EX-4.1) — 80KB
- d895981dex42.htm (EX-4.2) — 82KB
- d895981dex43.htm (EX-4.3) — 8KB
- d895981dex101.htm (EX-10.1) — 301KB
- d895981dex102.htm (EX-10.2) — 73KB
- g895981dsp96.jpg (GRAPHIC) — 27KB
- 0001193125-24-230283.txt ( ) — 893KB
- inab-20240930.xsd (EX-101.SCH) — 3KB
- inab-20240930_lab.xml (EX-101.LAB) — 18KB
- inab-20240930_pre.xml (EX-101.PRE) — 11KB
- d895981d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 4.2 Form of Series C Warrant. 4.3 Form of Amendment No. 1 to Common Stock Purchase Warrant (Series A). 10.1* Form of Securities Purchase Agreement, dated as of September 30, 2024. 10.2 Form of Registration Rights Agreement. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will supplementally furnish copies of omitted schedules and exhibits to the SEC or its staff upon its request. * Portions of this exhibit have been redacted in accordance with Item 601(b)(10) of Regulation S-K. The omitted information is not material and is the type that the registrant treats as private or confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Date: October 1, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)